FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W144958216> ?p ?o ?g. }

• W144958216 endingPage "380" @default.
• W144958216 startingPage "376" @default.
• W144958216 abstract "OBJECTIVES: The systemic and cognitive side effects of hepatitis C virus (HCV) therapy may be incapacitating, necessitating dose reductions or abandonment of therapy. Oral cannabinoid-containing medications (OCs) ameliorate chemotherapy-induced nausea and vomiting, as well as AIDS wasting syndrome. The efficacy of OCs in managing HCV treatment-related side effects is unknown. METHODS: All patients who initiated interferon-ribavirin therapy at The Ottawa Hospital Viral Hepatitis Clinic (Ottawa, Ontario) between August 2003 and January 2007 were identified using a computerized clinical database. The baseline characteristics of OC recipients were compared with those of nonrecipients. The treatment-related side effect response to OC was assessed by χ 2 analysis. The key therapeutic outcomes related to weight, interferon dose reduction and treatment outcomes were assessed by Student’s t test and χ 2 analysis. RESULTS: Twenty-five of 191 patients (13%) initiated OC use. Recipients had similar characteristics to nonrecipients, aside from prior marijuana smoking history (24% versus 10%, respectively; P=0.04). The median time to OC initiation was seven weeks. The most common indications for initiation of OC were anorexia (72%) and nausea (32%). Sixty-four per cent of all patients who received OC experienced subjective improvement in symptoms. The median weight loss before OC initiation was 4.5 kg. A trend toward greater median weight loss was noted at week 4 in patients eventually initiating OC use (−1.4 kg), compared with those who did not (−1.0 kg). Weight loss stabilized one month after OC initiation (median 0.5 kg additional loss). Interferon dose reductions were rare and did not differ by OC use (8% of OC recipients versus 5% of nonrecipients). The proportions of patients completing a full course of HCV therapy and achieving a sustained virological response were greater in OC recipients. CONCLUSIONS: The present retrospective cohort analysis found that OC use is often effective in managing HCV treatment-related symptoms that contribute to weight loss, and may stabilize weight decline once initiated." @default.
• W144958216 created "2016-06-24" @default.
• W144958216 creator A5009499168 @default.
• W144958216 creator A5049279040 @default.
• W144958216 creator A5055757054 @default.
• W144958216 date "2008-01-01" @default.
• W144958216 modified "2023-10-16" @default.
• W144958216 title "Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus" @default.
• W144958216 cites W114843108 @default.
• W144958216 cites W1606521211 @default.
• W144958216 cites W1983281937 @default.
• W144958216 cites W1991947875 @default.
• W144958216 cites W1996148437 @default.
• W144958216 cites W2001427377 @default.
• W144958216 cites W2006038739 @default.
• W144958216 cites W2011013410 @default.
• W144958216 cites W2027545702 @default.
• W144958216 cites W2056188558 @default.
• W144958216 cites W2058013973 @default.
• W144958216 cites W2058490108 @default.
• W144958216 cites W2061444097 @default.
• W144958216 cites W2068743551 @default.
• W144958216 cites W2077610326 @default.
• W144958216 cites W2088012386 @default.
• W144958216 cites W2090483583 @default.
• W144958216 cites W2093265950 @default.
• W144958216 cites W2094946038 @default.
• W144958216 cites W2112279043 @default.
• W144958216 cites W2127685726 @default.
• W144958216 cites W2140180096 @default.
• W144958216 cites W2140255682 @default.
• W144958216 cites W2165715544 @default.
• W144958216 cites W2165892706 @default.
• W144958216 cites W2171275714 @default.
• W144958216 cites W2186964192 @default.
• W144958216 cites W2317554121 @default.
• W144958216 cites W2326545597 @default.
• W144958216 cites W2333452860 @default.
• W144958216 doi "https://doi.org/10.1155/2008/725702" @default.
• W144958216 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2662895" @default.
• W144958216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18414712" @default.
• W144958216 hasPublicationYear "2008" @default.
• W144958216 type Work @default.
• W144958216 sameAs 144958216 @default.
• W144958216 citedByCount "30" @default.
• W144958216 countsByYear W1449582162012 @default.
• W144958216 countsByYear W1449582162013 @default.
• W144958216 countsByYear W1449582162014 @default.
• W144958216 countsByYear W1449582162015 @default.
• W144958216 countsByYear W1449582162017 @default.
• W144958216 countsByYear W1449582162018 @default.
• W144958216 countsByYear W1449582162019 @default.
• W144958216 countsByYear W1449582162021 @default.
• W144958216 countsByYear W1449582162022 @default.
• W144958216 crossrefType "journal-article" @default.
• W144958216 hasAuthorship W144958216A5009499168 @default.
• W144958216 hasAuthorship W144958216A5049279040 @default.
• W144958216 hasAuthorship W144958216A5055757054 @default.
• W144958216 hasBestOaLocation W1449582161 @default.
• W144958216 hasConcept C126322002 @default.
• W144958216 hasConcept C16005928 @default.
• W144958216 hasConcept C203014093 @default.
• W144958216 hasConcept C2522874641 @default.
• W144958216 hasConcept C2776360568 @default.
• W144958216 hasConcept C2776408679 @default.
• W144958216 hasConcept C2776455275 @default.
• W144958216 hasConcept C2778654693 @default.
• W144958216 hasConcept C2780040827 @default.
• W144958216 hasConcept C2780580376 @default.
• W144958216 hasConcept C2780852908 @default.
• W144958216 hasConcept C511355011 @default.
• W144958216 hasConcept C544821477 @default.
• W144958216 hasConcept C71924100 @default.
• W144958216 hasConcept C90924648 @default.
• W144958216 hasConceptScore W144958216C126322002 @default.
• W144958216 hasConceptScore W144958216C16005928 @default.
• W144958216 hasConceptScore W144958216C203014093 @default.
• W144958216 hasConceptScore W144958216C2522874641 @default.
• W144958216 hasConceptScore W144958216C2776360568 @default.
• W144958216 hasConceptScore W144958216C2776408679 @default.
• W144958216 hasConceptScore W144958216C2776455275 @default.
• W144958216 hasConceptScore W144958216C2778654693 @default.
• W144958216 hasConceptScore W144958216C2780040827 @default.
• W144958216 hasConceptScore W144958216C2780580376 @default.
• W144958216 hasConceptScore W144958216C2780852908 @default.
• W144958216 hasConceptScore W144958216C511355011 @default.
• W144958216 hasConceptScore W144958216C544821477 @default.
• W144958216 hasConceptScore W144958216C71924100 @default.
• W144958216 hasConceptScore W144958216C90924648 @default.
• W144958216 hasIssue "4" @default.
• W144958216 hasLocation W1449582161 @default.
• W144958216 hasLocation W1449582162 @default.
• W144958216 hasLocation W1449582163 @default.
• W144958216 hasLocation W1449582164 @default.
• W144958216 hasOpenAccess W144958216 @default.
• W144958216 hasPrimaryLocation W1449582161 @default.
• W144958216 hasRelatedWork W1504204244 @default.
• W144958216 hasRelatedWork W2370708261 @default.

• next